

# **DIABETES SERVICE SPECIFICATION**

Version Control	
V1.0 2025	25 March 2025

# Contents

1 INTRODUCTION	
2 CLINICAL SPECIFICATION	3
3 TRAINING & RESOURCES	
4 FEEDBACK AND LEARNING	
5 RECORDING OF INFORMATION	10
6 QUALITY	14
7 FINANCE	15
8 CONTRACT MONITORING	
Appendix 1 – Insulin Initiation Documents	
Appendix 2 – Diabetes Enhanced Service Codes (ESCRO)	20

#### DIABETES SERVICE SPECIFICATION

#### 1 INTRODUCTION

This Service Specification along with the Contract Details in Part 1 forms the Local Enhanced Service (LES) for the enhanced care of diabetes in primary care.

This Service Specification works towards meeting the Scottish Government priorities and NHSH Annual Delivery Plan (ADP): Outcome 3, Stay well and Outcome 4, Anchor well.

The numbers and prevalence of people with diabetes in Scotland continues to increase year on year. At the end of 2023 there were 353,088 people with a diagnosis of any type of diabetes in Scotland recorded in SCI-Diabetes - 310,541 (88%) are people with type 2 diabetes.

The number of new cases of type 2 diabetes (T2DM) has risen in Highland over the past 3 years, with Highland ranking third nationally in crude incidence of T2DM (559 per 100,000 population).

Associated with this will be a significant increase in the number of patients, with T2DM, who will be converted to insulin or GIP/GLP therapy. Traditionally these treatments would be managed in Secondary Care.

Practices should refer to appropriate local and national guidelines (including but not limited to TAM, SIGN and NICE).

#### 2 CLINICAL SPECIFICATION

### **Purpose**

The purpose of the LES is to provide a systematic, safe and reliable approach to diabetes care (for people aged 16 and over) to ensure patient care and safety; beyond what would be expected as core essential GMS services.

To encourage the setting of personalised targets; increase the proportion of people with diabetes receiving practice-based care; and to support the initiation of insulin and GIP/GLP1 in General Practice.

### **Definition**

For the purposes of this LES:

- T2DM Those with Hba1c at diagnosis >47 excluding those with Type1 Diabetes and Gestational Diabetes.
- Non-Complex T2DM Treated with two or fewer than two oral therapies for hyperglycaemia.
- Complex T2DM Treated with three or more oral therapies for hyperglycaemia or on an injectable therapy for diabetes.

#### **Service Aims**

- (i) To continue to support the development and maintenance of high-quality care for people with diabetes in Primary Care.
- (ii) To increase the proportion of people with diabetes being cared for in Primary Care and enable the referral and discharge of patients from Secondary Care in accordance with appropriate clinical guidance (including but not limited to TAM, SIGN and NICE).
- (iii) To support all patients being cared for in Primary Care to receive appropriate reviews conducted by the practice.
- (iv) To provide standardised and clinically effective insulin or GIP1/GLP initiation and management to patients.

## **General Requirements**

- (i) Practices should maintain an accurate register of patients with diabetes using appropriate READ codes; and ensuring that patient ethnicity is coded (with appropriate consent)
- (ii) Record the 'locus of care' (Practice Based or Shared Care or Specialist Care)

# Part 1 - Patients with Non-Complex Diabetes:

To provide care, including that expected as part of core essential GMS, to patients on the diabetes register with non-complex diabetes for whom the level of care expected, or required.

# **Service Requirements**

- (i) Ensure appropriate level of competency, through training (as appropriate, and dependant on clinician's role in care), to deliver an appropriate level of care for patients with non-complex diabetes (as defined above).
- (ii) Provide full support for non-complex T2DM patients in relation to their diabetes care
  - a) Practices would manage patients with non-complex T2DM either independently; or that have been referred to, and discharged from, DSN/secondary care services and maintained on a non-complex regime of treatment and where ongoing monitoring, support and education is provided in general practice:
    - i) As a minimum it is expected that these patients receive standard diabetes care as stated below:
      - 1. weight/BMI, BP
      - 2. bloods (including HbA1c, lipids & creatinine/eGFR),
      - 3. urinary ACR
      - recording of alcohol & smoking status (+/- brief intervention/smoking cessation advice)
      - 5. foot screening (frequency as appropriate based on risk pulses, sensation & risk categorisation)
      - 6. support self-monitoring of BMs/ketones where appropriate
    - ii) It is expected that patients with non-complex diabetes are offered at least 6 monthly reviews in Primary Care, as per NICE recommendations. As a minimum this would include updating HbA1c, weight/BMI & BP; and providing any appropriate adjustment to clinical care. Where individual clinical circumstances require more frequent review this should be provided.

- iii) Create/review & update a Personalised Diabetes Management Plan and agree personalised targets for HbA1c, Blood Pressure and weight/BMI.
- iv) Practices should refer to appropriate local and national guidelines (including but not limited to TAM. SIGN and NICE).
- v) Practices would be expected to monitor and manage risks associated with T2DM is the standard way (e.g. cardiovascular – management of cholesterol, BP; renal – management of micro/macroalbuminuria); and ensure that appropriate foot screening and engagement with vaccination and retinal screening programmes is supported.
- vi) Ensuring all relevant data is recorded within GPIT systems and transferrable to SCIdiabetes.

The contractor can trigger a claim for a patient under this service at any time; the following conditions apply:

- a) The contractor will ensure all requiring criteria has been met and coded prior to triggering a claim. Where a claim is triggered and the criteria has not been met within the required time frame, the claim will fail resulting in no payment. Where all criteria have been met with exception of the ACR, the lower fee will be paid.
- b) The overall payment will be paid at ½ of the annual fee for each of the annual and 6 monthly claims triggered.
- c) The maximum of one claim per patient within a 6-month period. Where a claim is triggered, in circumstances where criteria hasn't been met, no further claim(s) will be accepted for that patient until the 6-month period has lapsed.
- d) Where a patient moves practice, no further claim will be permitted against that patient CHI until the 6-month period has lapsed.

The use of DSNs and secondary care teams for advice and support on an ad-hoc basis would not preclude claiming under this LES, provided the full provision of care is based in General Practice.

### Part 2a – Patients with Complex Diabetes:

To provide care, including that expected as part of core essential GMS, to patients on the diabetes register with complex diabetes for whom the level of care expected, or required, can reasonably be delivered in a Primary Care setting.

### **Service Requirements**

(i) Ensure appropriate level of competency, through training (as appropriate, and dependant on clinician's role in care), to deliver an enhanced level of care for patients with complex diabetes (as defined above).

- (ii) Provide full or partial support for complex T2DM patients and/or those on injectable treatments for diabetes.
  - a) Practices signed up to deliver **Practice Based Care** would manage patients with complex T2DM either independently; or that have been referred to, and discharged from, DSN/secondary care services where they have been counselled and initiated by DSNs or secondary care; but where ongoing monitoring, support and education is provided in general practice (this could include complex oral diabetes regimens, and/or all forms of injectable therapies):
    - i) As a minimum it is expected that these patients receive standard diabetes care as stated below:
      - 1. weight/BMI, BP
      - 2. bloods (including HbA1c, lipids & creatinine/eGFR)
      - 3. urinary ACR
      - 4. recording of alcohol & smoking status (+/- brief intervention/smoking cessation advice)
      - 5. foot screening (frequency as appropriate based on risk pulses, sensation & risk categorisation)
      - 6. support self-monitoring of BMs/ketones where appropriate
    - ii) It is expected that patients with complex diabetes receiving Practice Based Care are offered at least 6 monthly reviews in Primary Care, as per NICE recommendations. As a minimum this would include updating HbA1c, weight/BMI & BP; and providing any appropriate adjustment to clinical care. Where individual clinical circumstances require more frequent review this should be provided.
    - iii) Create/review & update a Personalised Diabetes Management Plan and agree personalised targets for HbA1c, Blood Pressure and weight/BMI.
    - iv) Practices should refer to appropriate local and national guidelines (including but not limited to TAM, SIGN and NICE).
    - v) Practices would be expected to monitor and manage risks associated with T2DM is the standard way (e.g. cardiovascular – management of cholesterol, BP; renal – management of micro/macroalbuminuria); and ensure that appropriate foot screening and engagement with vaccination and retinal screening programmes is supported.
    - vi) Ensuring all relevant data is recorded within GPIT systems and transferrable to SCIdiabetes.
  - b) Practices signed up to deliver **Shared Care** for patients with either Type 1 or complex Type 2 Diabetes support delivery of care for patients, who remain under the care of the DSN or secondary care team, by providing annual:
    - i) Data collection
      - 1. weight/BMI, BP
      - 2. bloods (including HbA1c, lipids & creatinine/eGFR),
      - 3. urinary ACR
      - 4. recording of alcohol & smoking status (+/- brief intervention/smoking cessation advice)
      - 5. foot screening (frequency as appropriate based on risk pulses, sensation & risk categorisation)
      - 6. support self-monitoring of BMs/ketones where appropriate
    - ii) Practices would be expected to manage risks associated with T2DM is the standard way (e.g. cardiovascular management of cholesterol, BP, renal management of micro/macroalbuminuria); and ensure that appropriate foot screening and engagement with vaccination and retinal screening programmes is supported.

iii) Ensuring all relevant data is recorded within GPIT systems and transferrable to SCIdiabetes.

The contractor can trigger a claim for a patient under this service at any time; the following conditions apply:

- a) The contractor will ensure all requiring criteria has been met and coded prior to triggering a claim. Where a claim is triggered and the criteria has not been met within the required time frame, the claim will fail resulting in no payment. Where all criteria have been met with exception of the ACR, the lower fee will be paid.
- b) The overall payment for Practice Based Care will be paid at ½ of the annual fee for each of the annual and 6 monthly claims triggered. The overall payment for Shared Care will be paid when claims triggered.
- c) The maximum of one claim per patient within a 6-month period (Practice Based Care) and one claim per patient within a 12-month period (Shared Care). Where a claim is triggered, in circumstances where criteria hasn't been met, no further claim(s) will be accepted for that patient until the 6-month period has lapsed.
- d) Where a patient moves practice, no further claim will be permitted against that patient CHI until the respective 6-month or 12-month period has lapsed.

Initiation of injectables, including initial titration and optimisation, may be managed in specialist diabetes services, or under part 2 of this LES – but ongoing support/supervision could take place in primary care where individuals have stable glucose control and are achieving personal glucose targets, or in individuals treated with injectables who chose to have their ongoing care only within the general practice setting; and where primary care clinicians are competent to provide this level of care.

The use of DSNs and secondary care teams for advice and support on an ad hoc basis would not preclude claiming under either full or shared care.

### Part 2b – Initiation of Injectables for T2DM Patients with complex diabetes:

- (i) Practices signed up to deliver Initiations would be competent to counsel, initiate and monitor patients being escalated to injectable T2DM treatment regimens including the use of injectable GIP/GLP1 and insulin; including patient education.
- (ii) Payment covers only the initiation of treatment; and should be claimed in addition to either Practice Based or Shared Care for maintenance (see part 1 above).
- (iii) Initiation of injectable GIP/GLP1s
  - a) This would include counselling, initiation and monitoring of patients being started on injectable GIP/GLP1s; including patient education (and/or their carer and support staff where necessary).

- b) This would include a review at 3 and 6 months (including but not limited to HbA1c and weight) to assess ongoing appropriateness of therapies e.g. if no significant weight loss/reduction in HbA1c after 6 months of GIP/GLP1.
- c) The contractor will be eligible to claim for a patient if all the following conditions apply:
  - i) The contractor has the full clinical responsibility for the initiation and monitoring of the injectable GIP/GLP1 as above, and
  - ii) The contractor has issued a prescription for an injectable GIP/GLP1 within 1 month of the claim
  - iii) Note only one claim for initiation of GIP/GLP1 per patient can be made. The contractor should claim for monitoring (Practice Based or Shared, as appropriate) in addition to initiation.

# (iv) Initiation of Insulin in T2DM

- a) This would include counselling, initiation and monitoring of patients being started on insulin including patient education (and/or their carer and support staff where necessary).
- b) The contractor will be eligible to claim for a patient if all the following conditions apply:
  - i) The contractor has the full clinical responsibility for the initiation and monitoring of the insulin as above, and
  - ii) The contractor has issued a prescription for insulin within 1 month of the claim
  - iii) Note only one claim for initiation per patient can be made. The contractor should claim for monitoring (Practice Based or Shared, as appropriate) in addition to initiation.

The use of DSNs and secondary care teams for advice and support on an ad-hoc basis would not preclude claiming, provided the practice is undertaking the roles set out above.

### 3 TRAINING & RESOURCES

#### **Medical Staff:**

Core capabilities and competencies will have already been achieved in their GP training. All clinicians involved in delivering diabetes care will be expected to engage in appropriate updates to maintain their clinical knowledge every year as part of the annual appraisal process and work within their scope of practice as per the GMC's Good Medical Practice.

Prior to commencement of the service, providers must complete and submit the pre-audit for providers of diabetes care within the practice.

Doctors involved in diabetes care should conduct regular audits (including review of uptake and outcomes), be appraised on what they do and take part in necessary supportive educational activities.

Examples of generic core diabetes educational resources are listed below.

For Lead Clinicians looking to develop an extended role/GP with Specialist Interest (GPwSI) The University of Warwick offers a Postgraduate Diploma which can lead to an MSc in Diabetes is an online course over a year: <u>Diabetes</u>

# **Nursing Staff:**

Registered nurses can provide care and support to patients for diabetes care. Nurses providing diabetes care should be appropriately trained and competent taking into consideration their professional accountability and the Nursing and Midwifery Council guidelines on the scope of professional practice.

Where the practice initiates insulin, the Practice Nurse (or person initiating insulin with the patient) will need to ensure that they have also satisfactorily completed appropriate training. It is accepted that for practices new to an injectable initiation service (either insulin or GLP1/GIP) more support/advice may be required from specialist teams during the first year.

If a Practice has been undertaking the services as described above for several years, but does not possess an accredited qualification, then NHS Highland Deputy Medical Director and Associate Nurse Director for Community will consider each application to conduct the enhanced service on its merits.

Practices commencing on 1st April 2025 are permitted a one-year grace period for Primary Care Healthcare professionals to evidence and/or upskill their competencies.

Practices commencing after initial sign-up of 1st April 2025 are expected to have training in place prior to sign-up.

This training should be evidenced in the return audit.

# **Competency Assessments:**

Practices may wish to complete competency framework assessment for members of staff delivering diabetes care in Primary Care:

https://www.diabetes.org.uk/for-professionals/learning-and-development/competency-frameworks

In particular, the diabetes foot screening competencies and the Cambridge Diabetes Education Programme:

Diabetes Foot Screening – Foot Risk Awareness and Management Education (FRAME)

The Cambridge Diabetes Education Programme (CDEP) | Diabetes UK

### **Available sources of Training & Education:**

Online diabetes journals, education and resources for healthcare professional: <u>DiabetesontheNet | Online diabetes journals, education and resources for healthcare professionals.</u>

Diabetes courses for healthcare professionals | Diabetes UK

Pitstop Diabetes Training | Online and live courses are now available

# **Additional Support Resources:**

TAM: DIABETES | Right Decisions

Diabetes UK: Diabetes UK - Know diabetes. Fight diabetes. | Diabetes UK

My Diabetes My Way: Homepage | Information Site

New to Type 2 - Highland Diabetes App

Live It Highland Information Pack

#### 4 FEEDBACK AND LEARNING

The Practice will use the results of the Diabetes Clinical Audit and SCI-diabetes data as part of a discussion within the Practice on the effectiveness, efficiency and value of their practice services.

The Practice is encouraged to share any learning or action points from this discussion with other practices in their cluster.

### 5 RECORDING OF INFORMATION

Ensure the correct clinical coding and toolbar template is used to ensure compliance with the recording and monitoring requirements of the contract.

In addition to ensuring appropriate coding in line with provision of essential services, SCIdiabetes and the enhanced elements of the service; read codes will be used for monitoring and payment purposes:

ESCRO templates and codes are detailed in Appendix 2.

The following tables detail the required criteria and frequency for each patient group:

Specification Standards	Proposed Payment
All Non-Complex T2DM	£25.52
standards including ACR	
in previous 12m	
All Non-Complex T2DM	£20.52
standards without ACR in	
previous 12m	

All required criteria must be met and coded prior to triggering a claim. Where a claim is triggered, items that require to be done annually will be coded once within the preceding 12 months. Where a claim is triggered, items that require to be done 6 monthly will be coded once within the preceding 6 months.

monung will be coded once within the prec	
Ethnicity	Once
Type 1 Diabetes or	Once
Type 2 Diabetes	
T2DM Care or	Annually
Complex T2DM or	
Shared Care - Complex T2DM or	
Shared Care - Type 1 Diabetes Care	
BMI	Six Monthly
Blood Pressure	Six Monthly
HbA1c	Six Monthly
Smoking Status	Annually
U&E	Annually
ACE-i or ARB	Annually
	* Once if contraindicated / not tolerated /
	not indicated
Foot Screening	Annually
Frequency as appropriate based on risk	
<ul> <li>pulses, sensation &amp; risk categorisation</li> </ul>	
Alcohol intake recorded	Annually
Health Education – Exercise, Diet &	Annually
Weight Reduction	
Diabetes Dietary Review	Annually
Personalised Target Weight	Annually
Personalised Target HbA1c	Annually
Personalised Target BP	Annually
Lipids	Annually
Titrate Lipid Lowering Therapy or	Annually
Maximum Tolerated Lipid Lowering	* Once if contraindicated / not tolerated
Therapy or Statin	
Diabetes Management Plan Given	Annually
Urinary ACR	Annually
Albuminuria or	Annually
Microalbuminuria or	
Normal Urinary Albumin	

Specification Standards	Proposed Payment
Complex T2DM – Practice	£105.33
Based Care including ACR	
in previous 12m	
All Complex T2DM –	£100.33
Practice Based Care	
without ACR in previous	
12m	

All required criteria must be met and coded prior to triggering a claim. Where a claim is triggered, items that require to be done annually will be coded once within the preceding 12 months. Where a claim is triggered, items that require to be done 6 monthly will be coded once within the preceding 6 months.

monany win be dead once main the pred	bearing e memale.
Ethnicity	Once
Type 1 Diabetes or	Once
Type 2 Diabetes	
T2DM Care or	Annually
Complex T2DM or	
Shared Care - Complex T2DM or	
Shared Care - Type 1 Diabetes Care	
BMI	Six Monthly
Blood Pressure	Six Monthly
HbA1c	Six Monthly
Smoking Status	Annually
U&E	Annually
ACE-i or ARB	Annually
	* Once if contraindicated / not tolerated /
	not indicated
Foot Screening	Annually
Frequency as appropriate based on risk	
- pulses, sensation & risk categorisation	
Alcohol intake recorded	Annually
Health Education – Exercise, Diet &	Annually
Weight Reduction	
Diabetes Dietary Review	Annually
Personalised Target Weight	Annually
Personalised Target HbA1c	Annually
Personalised Target BP	Annually
Lipids	Annually
Titrate Lipid Lowering Therapy or	Annually
Maximum Tolerated Lipid Lowering	* Once if contraindicated / not tolerated
Therapy or statin	
Diabetes Management Plan Given	Annually
Urinary ACR	Annually
Albuminuria or	Annually
Microalbuminuria or	
Normal Urinary Albumin	
	reare and theresise for huneral vecessie or

\*Complex patient check based on three or more oral therapies for hyperglycaemia or on an injectable therapy for diabetes as defined in diabetic STU clusters. Automated – no coding required.

Specification Standards	Proposed Payment
Complex T2DM or T1DM –	£53.76
Shared Care including ACR	
in previous 12m	
All Complex T2DM or T1DM	£48.76
<ul> <li>Shared Care without</li> </ul>	
ACR in previous 12m	

All required criteria must be met and coded prior to triggering a claim. Where a claim is triggered, items that require to be done annually will be coded once within the preceding 12 months.

Ethnicity Once Type 1 Diabetes or Type 2 Diabetes T2DM Care or Complex T2DM or Shared Care - Complex T2DM or Shared Care - Type 1 Diabetes Care BMI Annually Blood Pressure Annually HbA1c Annually Smoking Status Annually U&E Annually ACE-i or ARB Annually * Once if contraindicated / not tolerated / not indicated Foot Screening Frequency as appropriate based on risk – pulses, sensation & risk categorisation Alcohol intake recorded Annually Health Education – Exercise, Diet & Weight Reduction Diabetes Dietary Review Annually Personalised Target Weight Annually Personalised Target HbA1c Annually Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Therese Other is annually Annually * Once if contraindicated / not tolerated / not indicated Annually  * Once if contraindicated / not tolerated / not indicated Annually Annually Annually Annually Annually Annually Annually Annually Annually	preceding 12 months.	
Type 2 Diabetes T2DM Care or Complex T2DM or Shared Care - Complex T2DM or Shared Care - Type 1 Diabetes Care BMI Blood Pressure HbA1c Smoking Status U&E Annually AcE-i or ARB Ace-i or ARB Annually Frequency as appropriate based on risk pulses, sensation & risk categorisation Alcohol intake recorded Health Education - Exercise, Diet & Weight Reduction Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Personalised Target BP Lipids Annually		Once
T2DM Care or Complex T2DM or Shared Care - Complex T2DM or Shared Care - Type 1 Diabetes Care  BMI Blood Pressure HbA1c Smoking Status U&E Annually ACE-i or ARB ACE-i or ARB Foot Screening Frequency as appropriate based on risk – pulses, sensation & risk categorisation Alcohol intake recorded Health Education – Exercise, Diet & Weight Reduction Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Personalised Target BP Lipids Annually	Type 1 Diabetes or	Once
Complex T2DM or Shared Care - Complex T2DM or Shared Care - Type 1 Diabetes Care  BMI Blood Pressure Annually HbA1c Annually Smoking Status Annually  ACE-i or ARB ACE-i or ARB Annually Frequency as appropriate based on risk - pulses, sensation & risk categorisation Alcohol intake recorded Health Education - Exercise, Diet & Weight Reduction Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Personalised Target BP Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually  Annually	Type 2 Diabetes	
Shared Care - Complex T2DM or Shared Care - Type 1 Diabetes Care  BMI Annually Blood Pressure Annually HbA1c Annually Smoking Status Annually  ACE-i or ARB Annually * Once if contraindicated / not tolerated / not indicated Annually Frequency as appropriate based on risk - pulses, sensation & risk categorisation Alcohol intake recorded Health Education - Exercise, Diet & Annually Weight Reduction Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Annually	T2DM Care or	Annually
Shared Care - Type 1 Diabetes Care  BMI Annually Blood Pressure Annually HbA1c Annually  Smoking Status Annually  U&E Annually  ACE-i or ARB Annually  * Once if contraindicated / not tolerated / not indicated  Foot Screening Frequency as appropriate based on risk - pulses, sensation & risk categorisation  Alcohol intake recorded Annually  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review Annually  Personalised Target Weight Annually  Personalised Target HbA1c Annually  Personalised Target BP Annually  Lipids Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually  Annually  Annually  Annually  Annually  Annually  Annually  Annually  Annually	Complex T2DM or	
BMI Annually Blood Pressure Annually HbA1c Annually Smoking Status Annually U&E Annually  ACE-i or ARB Annually  * Once if contraindicated / not tolerated / not indicated Foot Screening Frequency as appropriate based on risk - pulses, sensation & risk categorisation Alcohol intake recorded Annually Health Education - Exercise, Diet & Annually Weight Reduction Diabetes Dietary Review Annually Personalised Target Weight Annually Personalised Target HbA1c Annually Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually	Shared Care - Complex T2DM or	
Blood Pressure  HbA1c  Annually  Annually  U&E  Annually  ACE-i or ARB  Annually  * Once if contraindicated / not tolerated / not indicated  Foot Screening Frequency as appropriate based on risk  - pulses, sensation & risk categorisation  Alcohol intake recorded  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review  Personalised Target Weight  Personalised Target HbA1c  Personalised Target BP  Annually  Lipids  Annually	Shared Care - Type 1 Diabetes Care	
HbA1c Annually  U&E Annually  ACE-i or ARB Annually  Foot Screening Frequency as appropriate based on risk pulses, sensation & risk categorisation  Alcohol intake recorded Annually  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review Annually  Personalised Target Weight Annually  Personalised Target HbA1c Annually  Personalised Target BP Annually  Lipids Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually	BMI	Annually
Smoking Status  U&E  Annually  ACE-i or ARB  Annually  * Once if contraindicated / not tolerated / not indicated  Foot Screening Frequency as appropriate based on risk  - pulses, sensation & risk categorisation  Alcohol intake recorded  Annually  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review  Annually  Personalised Target Weight  Personalised Target HbA1c  Annually  Personalised Target BP  Annually  Lipids  Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually	Blood Pressure	Annually
U&E Annually  ACE-i or ARB Annually  * Once if contraindicated / not tolerated / not indicated  Foot Screening Frequency as appropriate based on risk – pulses, sensation & risk categorisation  Alcohol intake recorded Annually  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review Annually  Personalised Target Weight Annually  Personalised Target HbA1c Annually  Personalised Target BP Annually  Lipids Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually  Annually  Annually  Annually  Annually  Annually  Annually  Annually  Annually	HbA1c	Annually
ACE-i or ARB  Annually  * Once if contraindicated / not tolerated / not indicated  Foot Screening Frequency as appropriate based on risk  – pulses, sensation & risk categorisation  Alcohol intake recorded  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review  Annually  Personalised Target Weight  Personalised Target HbA1c  Personalised Target BP  Annually  Lipids  Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  Annually	Smoking Status	Annually
* Once if contraindicated / not tolerated / not indicated  Foot Screening Frequency as appropriate based on risk – pulses, sensation & risk categorisation  Alcohol intake recorded  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review  Personalised Target Weight  Personalised Target HbA1c  Personalised Target BP  Lipids  Annually  Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering  * Once if contraindicated / not tolerated / not indicated /	U&E	Annually
Foot Screening Frequency as appropriate based on risk – pulses, sensation & risk categorisation  Alcohol intake recorded Health Education – Exercise, Diet & Annually Weight Reduction Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Annually Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Annually Annually Annually	ACE-i or ARB	Annually
Foot Screening Frequency as appropriate based on risk  - pulses, sensation & risk categorisation  Alcohol intake recorded  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review  Personalised Target Weight  Personalised Target HbA1c  Personalised Target BP  Lipids  Annually  Titrate Lipid Lowering Therapy or  Maximum Tolerated Lipid Lowering		* Once if contraindicated / not tolerated /
Frequency as appropriate based on risk  – pulses, sensation & risk categorisation  Alcohol intake recorded  Health Education – Exercise, Diet & Annually  Weight Reduction  Diabetes Dietary Review  Personalised Target Weight  Personalised Target HbA1c  Personalised Target BP  Lipids  Annually  Titrate Lipid Lowering Therapy or  Maximum Tolerated Lipid Lowering		not indicated
<ul> <li>– pulses, sensation &amp; risk categorisation</li> <li>Alcohol intake recorded</li> <li>Health Education – Exercise, Diet &amp; Annually</li> <li>Weight Reduction</li> <li>Diabetes Dietary Review</li> <li>Personalised Target Weight</li> <li>Personalised Target HbA1c</li> <li>Personalised Target BP</li> <li>Annually</li> <li>Personalised Target BP</li> <li>Annually</li> <li>Titrate Lipid Lowering Therapy or Annually</li> <li>Maximum Tolerated Lipid Lowering</li> </ul>	Foot Screening	Annually
Alcohol intake recorded Health Education – Exercise, Diet & Annually Weight Reduction Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Annually Annually Annually	Frequency as appropriate based on risk	
Health Education – Exercise, Diet & Annually Weight Reduction Diabetes Dietary Review Annually Personalised Target Weight Annually Personalised Target HbA1c Annually Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Annually Maximum Tolerated Lipid Lowering	<ul> <li>pulses, sensation &amp; risk categorisation</li> </ul>	
Weight Reduction Diabetes Dietary Review Annually Personalised Target Weight Annually Personalised Target HbA1c Annually Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering	Alcohol intake recorded	Annually
Diabetes Dietary Review Personalised Target Weight Personalised Target HbA1c Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Annually	Health Education – Exercise, Diet &	Annually
Personalised Target Weight Personalised Target HbA1c Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Annually	Weight Reduction	
Personalised Target HbA1c Annually Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Annually Maximum Tolerated Lipid Lowering	Diabetes Dietary Review	Annually
Personalised Target BP Annually Lipids Annually Titrate Lipid Lowering Therapy or Annually Maximum Tolerated Lipid Lowering	Personalised Target Weight	Annually
Lipids Annually Titrate Lipid Lowering Therapy or Annually Maximum Tolerated Lipid Lowering	Personalised Target HbA1c	Annually
Titrate Lipid Lowering Therapy or Annually  Maximum Tolerated Lipid Lowering	Personalised Target BP	Annually
Maximum Tolerated Lipid Lowering	Lipids	Annually
Maximum Tolerated Lipid Lowering	Titrate Lipid Lowering Therapy or	Annually
,		
i nerapy or Statin	Therapy or Statin	* Once if contraindicated / no tolerated
Diabetes Management Plan Given Annually		Annually
Urinary ACR Annually		Annually
Albuminuria or Annually		Annually
Microalbuminuria or	Microalbuminuria or	
Normal Urinary Albumin	Normal Urinary Albumin	

Specification Standards	Proposed Payment
Other Injectable Initiation	£92.12
Insulin Initiation	£182.03

All required criteria must be met and coded, with insulin/GLP prescribed prior to triggering a claim at point of initiation. Payment covers only the initiation of treatment. Claimed in addition to either Practice Based or Shared Care for maintenance. All standards and coding complex and non-complex Practice based or Shared Care are required to be in place for the initiation claim to pass.

Diabetic on oral treatment & GLP-1	Once	
	*Only claimable once, per patient	
Insulin treatment initiated	Once	
	*Only claimable once, per patient	
Insulin initiation – Enhanced Service	Once per GLP / Insulin	
Admin		
Diabetic Education	Once per GLP / Insulin	
Diabetic injection administration	Once per GLP / Insulin	
education		
HbA1c	Three and Six Months post initiation	
Weight / BMI	Three and Six Months post initiation	
*Prescription check for GLP / Insulin within one month of claim. Automated - no		

<sup>\*</sup>Prescription check for GLP / Insulin within one month of claim. Automated – no coding required.

### 6 QUALITY

The GP will hold medical responsibility for the patient under this LES.

The service is provided by appropriately trained and qualified Practice Nurses, Advanced Nurse Practitioners and General Practitioners.

A collaborative approach between General Practice and Secondary Care colleagues (DSNs and Consultants) to provide specialist advice to support GPs to manage these patients, where necessary, is encouraged.

Diabetes should be managed in line with TAM, SIGN and NICE guidance.

# Record keeping:

Production of an appropriate clinical record using appropriate read codes and adequate recording should be made in the patient's electronic record and appropriate national systems (such as SCI-diabetes).

# **Referral policies:**

When appropriate to refer patients promptly to other necessary services and to the relevant support agencies using locally agreed guidelines.

# **Monitoring and Feedback:**

Where practices have undertaken work through this service, feedback may be provided where patients have required significant subsequent input by DSNs to support ongoing quality improvement. This may require service providers to undertake additional training.

### 7 FINANCE

No payment can be claimed for patients being fully monitored under secondary care.

#### **Contract value**

Payment per patient claimed:

All Non-Complex T2DM standards without ACR in previous 12m: £20.52 All Non-Complex T2DM standards including ACR in previous 12m: £25.52

Contractors can claim for non-complex care when they are satisfied ALL standards with exception of ACR (as per Part 1) for the patient have been met, failure to meet any other required standards will result in no payment. Failing to record an ACR will reduce the payment by £5.00, adjusted annually as per 4.0 of Part 3 of the overall contract. Maximum of one claim (paid at ½ of the annual fee for each) per patient within a 6-month period.

All Complex T2DM – Practice Based Care without ACR in previous 12m: £100.33
All Complex T2DM – Practice Based Care including ACR in previous 12m: £105.33
All Complex T2DM or T1DM – Shared Care without ACR in previous 12m: £48.76
All Complex T2DM or T1DM – Shared Care including ACR in previous 12m: £53.76

Contractors can claim for practice based complex care when they are satisfied ALL standards with exception of ACR (as per Part 2a) for the patient have been met, failure to meet any other required standards will result in no payment. Failing to record an ACR will reduce the payment by £5.00, adjusted annually as per 4.0 of Part 3 of the overall contract. Maximum of one claim (paid at ½ of the annual fee for each) per patient within a 6-month period.

Contractors can claim for shared complex care when they are satisfied ALL standards with exception of ACR (as per Part 2a) for the patient have been met, failure to meet any other required standards will result in no payment. Failing to record an ACR will reduce the payment by £5.00, adjusted annually as per 4.0 of Part 3 of the overall contract. Maximum of one claim per patient within a 12-month period.

Other Injectable Initiation: £92.11 Insulin Initiation: £182.03

DSNs and Diabetes Specialists will support feedback on individual patient care. Where significant additional input to patient care is required to reach the standard set out in this specification the payment associated will be recovered.

Maximum of one claim per patient per GLP and Insulin.

## **Payment**

Payments will be made in accordance with claims by practice, paid in arrears. Satisfying all Practice Based Non-complex and Complex T2DM standards within the preceding 12 months will trigger 1/2 payment. Full payment achievable by making two claims in 12-month period. Satisfying all Shared Care Complex T2DM or T1DM standards within the preceding 12 months will trigger full payment on making a claim.

Payments for Initiation (as per part 2b of specification) will be made on a monthly basis in arrears. Practice will trigger a claim in the same month as the initiation prescription is generated and all initiation of injectables standards have been met. 3 and 6 monthly post-initiation reviews and standards are subject to quality assurance / payment verification as detailed in Part 1, Paragraph 5 of the overall contract. The practice will provide evidence in instances of unmet standards. Failing to demonstrate intent will result in recoveries as detailed in Part 1, Paragraph 5.3 of the overall contract.

Payment is subject to the practice meeting the terms and conditions of the Clinical Specification in section 2.

#### 8 CONTRACT MONITORING

# **Specific Requirement**

Monitoring of this LES will be done through monthly submission/extraction via the reporting tool managed by NSS (Albasoft) analytics using the appropriate READ codes as defined in the clinical specification.

#### **Contract Review**

Quality indicators are as detailed in section 3.0 of the contract. For the Contract period the contract review element of the Annual Review will be on the items covered in Section 2.0

#### Verification

Ad hoc post payment verification will take place as per 4.2 of the contract agreement.

# **Appendix 1 – Insulin Initiation Documents**

Stage 1 – Day of insulin initiation

# **Topics of discussion and practice**

Benefits of insulin for people with Type 2 Diabetes

Injection technique:

Clinician demonstrates injection technique and patient demonstrates technique back to Clinician.

Dummy injection or actual injection completed by patient.

Details of injections:

Provide written simple instructions

When to take doses

How much insulin to take

Injection site rotation

Storage of insulin

How and when to discard needles and pen devices.

Blood glucose testing:

Frequency of testing

Blood glucose targets

Inform patients insulin commenced at low dose with expectation doses will need to be increased.

Hypoglycaemia:

Inform patient what level is a hypo

Signs and symptoms

Treatment

Causes/prevention

**Driving regulations:** 

Inform patient of legal obligation to inform DVLA and insurance company

Regulations around blood glucose testing and driving

Provide written documentation

Basic dietary advice:

Importance of carbohydrates at each meal

Define carbohydrates

Advise of possible weight gain with insulin

Obtain consent to refer to Dietitian and refer

Ensure patient has supply/prescription arranged for:

4 mm needles

Insulin pens/cartridges

Sharps box

Knows what medications to stop/continue

Follow up details:

Provide contact details

Indicate when to call after commencing first injection.

Arrange follow up appointment within 1 week

### Stage 2 - Review within 1 week of insulin initiation

# Topics of discussion and practice

Discuss patients concerns/issues with treatment

Review injection technique:

Patient is able to demonstrate to Clinician or talk through correct insulin injection technique

Review details of injections:

Timing of when patient is taking their doses

How much insulin patient has been taking

Injection site rotation

Storage of insulin

Ensure needle changed every injection.

Review hypoglycaemia and driving regulations

Patient is able to re-iterate to Clinician how to identify and treat a hypo

Ensure patient has informed DVLA and insurance company of insulin commencement

Review blood glucose readings and discuss with patient principles of insulin dose adjustment using patient's own readings.

Provide patient with insulin adjustment algorithm

**Basic Dietary Advice:** 

Discuss importance of healthy eating in the management of diabetes and benefits even with some weight loss.

Remind patient of importance of having carbohydrates at each meal.

Sick day rules:

Ensure patient is aware to continue insulin

Advise increase in blood glucose testing

Suggest food substitutes if experiencing nausea/vomiting

Medicines advice card discussed and given

When to seek help and who from

Support networks:

Provide Diabetes UK contact details and inform of local group

Inform about My Diabetes My Way

**ENGAGE** 

Inform of follow up contact/appointment

Appointment within a month

Consider telephone/email contact prior

### Stage 3 – Review within 1 month of insulin initiation

# Topics of discussion and practice

Discuss patients concerns/issues with treatment

Review blood glucose readings:

Encourage patient to consider where patterns in readings are emerging.

Encourage patient to consider which doses of insulin and by how much should be adjusted.

Long term complications of diabetes:

How to reduce risk factors

Annual screening

Smoking (if applicable)

Need for contraception until glycaemic control in target range (if applicable).

### Physical activity:

Discuss benefits of exercise in the management of type 2 diabetes

If appropriate, discuss possible insulin dose adjustment relating to physical activity

Review sick day advice:

Ensure patient is aware to continue insulin

Need to increase blood glucose tests

Discuss food substitutes if experiencing nausea/vomiting

Patient can re-iterate when to seek help and who from

#### Alcohol:

Explain alcohol increases the risk of delayed hypoglycaemia

Advise of need to have food while drinking alcohol

Advise not to take extra insulin to counteract high blood glucose levels.

Inform of follow up contact/appointment

# Appendix 2 - Diabetes Enhanced Service Codes (ESCRO)

ESCRO – Diabetes V4.1 (13/03/2025)

Note: [P] next to header means 1 tab from each line is required for payment

[P] next to line indicates that 1 tab from that line is required for payment

Purple highlight – QoF related minimum requirements for all patients

Green highlight - All annual requirements

Yellow highlight – 3mthly review requirements for GIP/GLP1 initiation claims

Orange highlights – 6mthly review minimum requirements for all practice based care patients

Enhanced Service Claim [P]

Non-Complex T2DM Care or

Practice Based Care - Complex T2DM or

Shared Care - Complex T2DM or Shared Care - Type 1 Diabetes Care and / or

Initiation GIP/GLP1s or Initiation of Insulin

Diagnosis & Care (code once rather than annual)

[P] Ethnicity – See below (code once not annual – pull existing codes if possible)

[P] Type 1 Diabetes – C10E or Type 2 Diabetes – C10F

Diabetes in Remission – C10P or Gestational Diabetes – C2B or Pre-Diabetes

Data Collection [P] (required for ALL patients with Diabetes, regardless of type or care arrangement)

Height (m) - 229 and Weight (kg) - 22A and BMI - 22K

3 month review weight – 22A (required for GIP/GLP1 initiation) 6month weight – 22A and 6month BMI – 22K

Blood Pressure – 246 or BP declined – 813Y. and 6month Blood Pressure – 246 or

6month BP declined – 8I3Y.

**Smoking Status** 

Never smoked - 1371 or Current Smoker - 137R or Ex-smoker - 137S

Smoking cessation advice given – 8CAL (if appropriate)

Physical Activity

Alcohol Consumption - 136 FAST score +/- Alcohol Brief Intervention (if appropriate)

Bloods taken (HbA1c – 42W5, U&E's – 451F, lipids – 44PH) Urine sent (urinary ACR – 46W)

3 month HbA1c – 42W5 (required for GIP/GLP1 initiation claim) 6 month HbA1c – 42W5

Depression Screening (freetext comments)

Foot screening (via SCI diabetes link)

Left foot pulse(s) present – 22FB or Left foot pulses absent – 24FA

Right foot pulse(s) present – 24EB or Right foot pulses absent – 24EA

Left foot monofilament normal – 29BC or Left foot monofilament abnormal – 29BA

Right foot monofilament normal – 29BB or Right foot monofilament abnormal – 29B9

Left foot Risk Category and Right Foot Risk Category (?use existing drop boxes)

Low risk – 25GI Low risk – 2G5E

Moderate risk – 2G5F Moderate risk – 2G5F

High Risk – 2G5K High Risk – 2G5G

Ulcerated – 2G5L Ulcerated – 2G5H

Retinal Screening (not attached to payment)

Digital Retinopathy Screening or Retinopathy Screening Declined/Refused

Left Eye no Diabetic Retinopathy or Left Eye Diabetic Retinopathy

Right Eye no Diabetic Retinopathy or Right Eye Diabetic Retinopathy

Immunisation (can add additional options if required to record vaccines given/declined)

Influenza Vaccine recommended or Influenza Vaccine contraindicated or Influenza Vaccine declined

COVID Vaccine recommended or COVID Vaccine contraindicated or COVID Vaccine declined

Other Vaccine recommended or Other Vaccine contraindicated or Other Vaccine declined

Diet & Lifestyle Advice [P] (required for patients with Diabetes not under alternate service)

Smoking cessation Advice Given and/or Signposted/referred to Smoking Cessation Support

Health Education - Alcohol FAST score +/- Alcohol Brief Intervention (if appropriate)

Health Education – Exercise

Health Education – Diet in Diabetes

Type 1 Diabetes Dietary Review or Type 2 Diabetes Dietary Review

Health Education – Weight Reduction (agree target 5-10% reduction) Target Weight – 66CF

Target BMI – 22KA

Diabetes Review [P] (required for patients with Diabetes not under alternate service)

Annual Diabetes Review or 3 month review or 6 month review

HbA1c mmol/mol Personalised Target HbA1c – 66Ae
Diet/Lifestyle Only or Oral Treatment or Non-insulin Injectable or Insulin Injectable
Diabetes Control – add freetext box to document changes to diabetes treatments
Total Cholesterol (add units) Serum HDL (add units)
Titrate Lipid Lowering Therapy or Maximum Tolerated Lipid Lowering Therapy
or Statin not Indicated – 8163 or Statin Contraindicated or Statin Not Tolerated – 8176
or Statin Declined 813C Show Statin Scripts
BP Personalised Target BP – 246K / 246L
eGFR (add units) serum Creatinine (add units) Urinary ACR
Albuminuria – R1100 or Microalbuminuria – R1103 or Normal Urinary Albumin – 46N1
ACE-i Prophylaxis – 8B6B or ACE-i Contraindicated – 8I28 or ACE-i not Tolerated – U60C4
or ACE-i Declined – 8I3D or ACE-i /ARB Not Indicated – 8I64
ARB Prophylaxis – 8B6E or ARB Contraindicated – 8I2H or ARB not Tolerated – U060CB
or ARB Declined – 8I3D
Management
[P] Diabetes Management Plan Given – 66AR (freetext comments) Add recall
Refer to Diabetes Consultant (freetext comments)
Seen by Diabetes Consultant (freetext comments)
Refer to Diabetes Specialist Nurses (freetext comments)
Seen by Diabetes Specialist Nurses (freetext comments)
GIP/GLP1 Initiation
Initial Educational Appointment or <mark>3 month review</mark> or <mark>6 month review</mark>
3 month HbA1c – 42W5 and 3 month review weight – 22A
Injection Technique
Awaiting DSN info. but aim similar to insulin section
Insulin Initiation
Initial Educational Appointment
Injection Technique Blood Glucose Testing Hypoglycaemia Advice
Driving Dietary Advice Follow up arrangements

# Resources

(Add links to TAM and referral/signposting info for SilverCloud, CBT, Weight Management, Smoking Cessation, My DiabetesMy Way, New to Type 2, LiveIt Highland etc)

Read codes 13/03/25	Screen description	Read code description	When to be used	SCI DC Check	Old ES Check
Enhanced Se	rvice Claim [P]				
C10F	Type 2 diabetes mellitus	Type 2 diabetes mellitus	Non-Complex T2DM Care	Υ	Υ
66AP. + C10F + C1093	Practice programme	Diabetes: practice programme	Practice Based Care - Complex T2DM	Y	N (C1093)
66AQ. + C10F + C1093	Shared care programme	Diabetes: shared care programme	Shared Care - Complex T2DM	Y	N (C1093)
66AQ. + C10E			Shared Care - Type 1 Diabetes Care	Υ	Υ
6605.	Diabetc on oral trtmnt & GLP-1		Initiation GIP/GLP1s	N	N
9kL		Insulin init - enh serv admin	Initiation GIP/GLP1s	N	N
.66Ap	Insulin treatment initiated		Initiation of Insulin	Υ	N
9kL		Insulin init - enh serv admin	Initiation of Insulin	N	N
Diagnosis &	Care (code once rather the				
Ethnicity (Dr	op down) - (code once no	ot annual – pull existing o	codes if possible)		
9i21.	Scottish	Scottish – Ethnic cat 2001 census		N	Y
9i0	Other British	British or mixed British 2001 cen		N	Y
9i1	Irish	Irish – Ethnic category 2001 cen		N	Y
9i2	Any other White background	Other white – Ethnic categ 2001 cen		N	Y
9i6		Other mixed – Ethnic cat 2001 cen		N	Υ
9i7	Indian	Indian or British Indian 2001 cen		N	Υ
9i8	Pakistani	Pakistani or Brit Pakistani 2001 cen		N	Υ
9i9	Bangladeshi	Bangladeshi or Brit Bangl 2001 cen		N	Υ
9iE	Chinese	Chinese – Ethnic category 2001 cen		N	Y
9iA	Any other Asian background	Other Asian – Ethnic cat 2001 cen		N	Y
9iB	Caribbean	Caribbean – Ethnic categ 2001 cen		N	Y
9iC	African	African – Ethnic category 2001 cen		N	Y
9iD	Any other Black background	Other Black – Ethnic cat 2001 cen		N	Υ
9iF	Any other Ethnic background	Other Ethnic – Ethnic cat 2001 cen		N	Y

9iG	Ethnic category not stated	Ethnic category not stated	Refused by patient	N	Y
C10E.			Type 1 Diabetes	Υ	Υ
C10F.			Type 2 Diabetes	Υ	Υ
C10P.		Diabetes mellitus in remission	Diabetes in Remission	N	N
C2B		Gestational diabetes mellitus	Gestational Diabetes	N	N
14080	High risk of diabetes mellitus	High risk of diabetes mellitus	Pre-Diabetes	N	N
	ection [P] (required for ALL p	patients with Diabetes, re	gardless of type or care		
arrangeme 229	Height	O/E - height	Height (m)	Υ	Υ
22A	Weight	O/E - Weight	Weight (kg)	Y	Y
		Body Mass Index	BMI	Y	Y
22K	Body Mass Index	,		Y	Y
22A.	Weight	O/E - Weight	3 month review weight		
22A.	Weight	O/E - Weight	6month weight	Y	Y
22K	Body Mass Index	Body Mass Index	6month BMI	Υ	Υ
246.	Blood pressure	O/E - blood pressure	Blood Pressure	Υ	N
8I3Y.	BP Refused	BP procedure refused	Blood pressure procedure refused	Υ	Y
246.	Blood pressure	O/E - blood pressure	6month Blood Pressure	Υ	N
8I3Y.	BP Refused	BP procedure refused	Blood pressure procedure refused	Y	Y
Smoking (	Drop down)				
1371.	Never smoked tobacco	Never smoked tobacco	Never smoked	Υ	Υ
137R.	Current smoker	Current smoker	Current Smoker	Υ	Υ
137S.	Ex smoker	Ex smoker	Ex-smoker	Υ	Υ
8CAL.	Smoking cessation advice	Smoking cessation advice	Smoking cessation advice given	Υ	Υ
Physical A	ctivity (Drop down)				
1383.	Enjoys light exercise	Enjoys light exercise		Υ	Υ
1384.	Enjoys moderate exercise	Enjoys moderate exercise		Υ	Y
1385.	Enjoys heavy exercise	Enjoys heavy exercise		Υ	Υ
1382.	Avoids even trivial exercise	Avoids even trivial exercise		Υ	Y
1381.	Exercise physically impossible	Exercise physically impossible		Υ	Y
136	Alcohol consumption	Alcohol consumption	Alcohol Consumption	Υ	Y
388u	Record FAST Screening +	Fast alcohol screening test	FAST score	N	N
	Score				
9k16.	NA - automated	Alcohol screen completed	Automated when recording FAST using Escro - claim	N	N
38D3	AUDIT Score	Alcohol use disorders identification test	To record AUDIT score	N	N
9k1A.	Record Brief Intervention provided	Brief intervention for excessive alcohol consumption completed -	To record ABI provided under LES - claim	N	N

	claim			
en <mark>We need to check this is</mark>	the codes recorded who	en bloods are recorded		
		HbA1c	Υ	Υ
		U&E's	Υ	Υ
Total cholesterol measurement	Total cholesterol measurement	Lipids	Υ	Y
,	Urine microalbumin (& level)	(& Urine sent Y		Y
		3 month HbA1c Y		Υ
		6 month HbA1c		Υ
	ts with Diabetes, regardl	ess of type or care		
Depression screening		Depression Screening	Υ	Y
ning	1			
		Left foot pulse(s) present	Υ	Υ
		Left foot pulses absent	Υ	Υ
		Right foot pulse(s) present	Υ	Υ
		Right foot pulses absent	Υ	Υ
		Left foot monofilament normal	Υ	Υ
		Left foot monofilament abnormal	Y	Y
		Right foot monofilament normal	Y	Y
		Right foot monofilament abnormal	Y	Υ
tisk Category (Drop down) 8	k Right foot Risk Catego	ry (Drop down)		
L		Low risk	Υ	Υ
L		Moderate risk	Υ	Υ
L		High Risk		Υ
L		Ulcerated Y		Υ
R		Low risk Y		Υ
R		Moderate risk Y		Υ
R		High Risk Y		Υ
R		Ulcerated	Υ	Υ
reening				
		Digital Retinopathy Screening	Υ	Υ
		Retinopathy Screening Declined/Refused	Y	Y
Background? Preproliferative?		Left Eye no Diabetic Retinopathy		
Background? Preproliferative?		Left Eye Diabetic Retinopathy		
Preproliferative?		Right Eye no Diabetic Retinopathy		
tion	ı	, , , , , , , , , , , , , , , , , , ,		
		Influenza Vaccine		
	Total cholesterol measurement Urine microalbumin (& level)  [P] (required for ALL patient ent)  Depression screening completed ning  L  L  L  R  R  R  R  R  R  R  Reening  Background?  Preproliferative?  Background?  Preproliferative?  Background?  Preproliferative?  Background?  Preproliferative?  Background?  Preproliferative?  Background?  Preproliferative?	We need to check this is the codes recorded when the c	we need to check this is the codes recorded when bloods are recorded    HbA1c	en We need to check this is the codes recorded when bloods are recorded    HbA1c

8I2F			Influenza Vaccine Y contraindicated		Υ
9OX5			Influenza Vaccine declined	Υ	Υ
			COVID Vaccine recommended		
			COVID Vaccine contraindicated		
			COVID Vaccine declined		
			Other Vaccine recommended		
			Other Vaccine contraindicated		
			Other Vaccine declined		
Diet & Lifest		r patients with Diabetes	not under alternate service)		
8CAL.	Smoking cessation	Smoking cessation	Smoking cessation advice	Υ	Υ
OC/ (L.	advice	advice	given	·	•
8H7i.			Signposted/referred to Smoking Cessation Support		N
			Health Education - Alcohol	Υ	Υ
.6792					
388u	Record FAST Screening + Score	Fast alcohol screening test	FAST score	N	N
9k16.	NA - automated	Alcohol screen completed	Automated when recording FAST using Escro - claim	N	N
38D3	AUDIT Score	Alcohol use disorders identification test	To record AUDIT score	N	N
9k1A.	Record Brief Intervention provided	Brief intervention for excessive alcohol consumption completed - claim	To record ABI provided under LES - claim	N	Z
6798.			Health Education – Exercise	Υ	Υ
8CA41			Health Education – Diet in Diabetes	Υ	Υ
66At0			Type 1 Diabetes Dietary Review	N	N
66At1			Type 2 Diabetes Dietary Review	N	N
8CA40			Health Education – Weight Reduction	Y	Υ
66CF			Target Weight	N	N
22KA.			Target BMI	N	N
Diabetes Re	view [P] (required for pati	ents with Diabetes not u	nder alternate service)		
9OLZ 66AS		Diabetes monitoring administration	Annual Diabetes Review	Y (66AS)	N
9OLZ 66Ai		Diabetic 6 month review	6 month review	Y (66Ai)	N
9OLZ (code on own withou 6m or Annual?)	t		3 month review	N	N
42W5.			HbA1c	Υ	Υ
66Ae			Personalised Target HbA1c	Υ	N
66A3.			Diet/Lifestyle Only	Υ	Υ

66A4.		Diabetic on oral treatment	Oral Treatment	Y	Y
66As.		Diab on subcutaneous treatment	Non-insulin Injectable	Y	N
66A5.		Diabetic on insulin	Insulin Injectable	Υ	Υ
66AH.		Diabetic treatment changed	Diabetes Control	Y	N
44PH.		Total cholesterol:HDL	Total Cholesterol	Y	Y
44P5.		Serum HDL cholesterol	Serum HDL	Y	Y
66X2.	Lipid disord treatment changed	Lipid disord treatment changed	Titrate Lipid Lowering Therapy	N	
8BL1.		Pt on max tol lipid low ther	Maximum Tolerated Lipid Lowering Therapy	Υ	Υ
8163.		Statin not indicated	Statin not Indicated	Υ	Υ
8127.		Statins contraindicated	Statin Contraindicated	Υ	Υ
8176.		Statin not tolerated	Statin Not Tolerated	Υ	Υ
813C.		Statin declined	Statin Declined	Υ	Υ
	For NSS to advise if possible		Show Statin Scripts		
246.	Blood pressure	O/E - blood pressure	Blood Pressure	Υ	N
8I3Y.	BP Refused	BP procedure refused	Blood pressure procedure refused	Y	Y
246K		Target systolic blood pressure	Personalised Target BP	Y	N
451F.		Glomerular filtration rate	eGFR	Υ	Y
44J3.		Serum creatinine	serum Creatinine	Υ	Υ
46TC.		Urine albumin:creatinine ratio	Urinary ACR	Υ	Y
R1100		[D]Albuminuria	Albuminuria	Υ	Υ
R1103		[D]Microalbuminuria	Microalbuminuria	Υ	Υ
46N1	Urine protein normal	Urine protein normal	Normal Urinary Albumin	Υ	Υ
8B6B.		ACE inhibitor prophylaxis	ACE-i Prophylaxis	Υ	Y
8128.		ACE inhibitors contraindicated	ACE-i Contraindicated	Υ	Υ
8174.		ACE inhibitor not tolerated	ACE-i not Tolerated	Y	N
813D.		ACE inhibitor declined	ACE-i Declined	Υ	Υ
8164	ACE inhibitor not indicated	ACE inhibitor not indicated	ACE-i /ARB Not Indicated	Υ	N
8B6E		Angtens II recep antag prophyl	ARB Prophylaxis	Υ	Υ
812H		Angtensin II recpt ant contra	ARB Contraindicated	Υ	Υ
8175		Angioten II recpt antg not tol	ARB not Tolerated	Υ	N
813D		ACE inhibitor declined	ARB Declined	Υ	Υ
Managem	ent				
66AR	Diabetes management plan given	Diabetes management plan given	Diabetes Management Plan Given	Υ	Υ

	For NSS to advise if possible		Add recall			
8H4F	Referral to diabetologist	Referral to diabetologis	tRefer to Diab	etes Consultant	Υ	N
9N2d	Seen by diabetologist	Seen by diabetologist	Seen by Diabetes Consultant		Υ	N
8HI4 or 8H7C	Referral to community diabetes specialist nurse or Refer, diabetic liaison nurse		Refer to Diab Nurses	etes Specialist	N (8HI4) Y (8H7C)	N
9N0n or 9N2i	Seen in community diabetes specialist clinic or Seen by diabetic liaison nurse		Seen by Diab Nurses	etes Specialist	N (9N0n) Y (9N2i)	N
GIP/GLP1 Ini	tiation					
66Af	Pt diabetes education	Pt diabetes education	Initial Educati		Υ	Ν
6646	review	review	Appointment			
66Af	Pt diabetes education review	Pt diabetes education review	3 month revie	9W	Υ	N
66Af	Pt diabetes education review	Pt diabetes education review	6 month revie	ew	Y	N
42W5.		HbA1c levl - IFCC standardised	3 month HbA	<b>1</b> 1c	Y	Υ
22A		O/E - weight	3 month review weight		Υ	Υ
6791	Diabetic injection administration education		Injection Tech	nnique	N	N
			Awaiting DSN similar to insu	l info. but aim ulin section		
Insulin Initia	tion					
679c.	Insulin administratn education	Insulin administratn education	Initial Educati Appointment		N	N
6791	Diabetic injection administration education		Injection Tech	nnique	N	N
8CAQ	Advice about blood gluc contrl	Advice about blood gluc contrl	Blood Glucose Testing N		N	N
679L1	Hypoglycaemia education	Hypoglycaemia education	Hypoglycaemia Advice		N	N
679L2	Advice about diabetes driving		Driving Dietary Advice		N	N
			Follow up arr	angements		
Resources						
TAM		https://rightdecisions.sc -treatments-and-medic highland/adult-therape guidelines/diabetes	ines-nhs- utic-			
Referral/signposting info for SilverCloud CBT		https://rightdecisions.scot.nhs.uk/tam -treatments-and-medicines-nhs- highland/adult-therapeutic- guidelines/mental- health/psychological-services- guidelines/computerised-cognitive- behavioural-therapy-ccbt- guidelines/?searchTerm=silvercloud		Dinformation	n/LIVE%2	
СВТ		galacinics, iscarcinienn	Silvercioud			

Weight Management	https://rightdecisions.scot.nhs.uk/tam https://www.myself-
	-treatments-and-medicines-nhs- management.org/
	highland/adult-therapeutic-
	guidelines/food-fluid-and-
	nutrition/weight-and-health-
	guidelines/dietetic-service-referral-
	guidelines/?searchTerm=weight%20
	management
Smoking Cessation	https://rightdecisions.scot.nhs.uk/tam https://www.smokefreehighland.scot.
	-treatments-and-medicines-nhs- nhs.uk/
	highland/adult-therapeutic-
	guidelines/mental-health/smoking-
	cessation-
	guidelines/?searchTerm=smoking%2
	0cessation 0cessation
My DiabetesMy Way	https://mydiabetesmyway.scot.nhs.uk
	/
New to Type 2	https://www.nhshighland.scot.nhs.uk/
	media/oeoaldnk/new-to-type-2-
	highland-app.pdf
Livelt Highland	https://www.nhshighland.scot.nhs.uk/
	media/phmlov0a/live-it-highland-
	participants-pack.pdf
NHS Highland Website	https://www.nhshighland.scot.nhs.uk/
	health-and-
	wellbeing/diabetes/diabetes-
	resources-in-highland/